A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä
Absence of polysialylated NCAM is an unfavorable prognostic phenotype for advanced stage neuroblastoma




Julkaisun tekijät: Korja M, Jokilammi A, Salmi TT, Kalimo H, Pelliniemi TT, Isola J, Rantala I, Haapasalo H, Finne J
Kustantaja: BMC
Julkaisuvuosi: 2009
Journal: BMC Cancer
Tietokannassa oleva lehden nimi: BMC cancer
Lehden akronyymi: BMC Cancer
Volyymi: 9
ISSN: 1471-2407
eISSN: 1471-2407

Tiivistelmä
The expression of a neural crest stem cell marker, polysialic acid (polySia), and its main carrier, neural cell adhesion molecule (NCAM), have been detected in some malignant tumors with high metastatic activity and unfavorable prognosis, but the diagnostic and prognostic value of polySia-NCAM in neuroblastoma is unclear.\nA tumor tissue microarray (TMA) of 36 paraffin-embedded neuroblastoma samples was utilized to detect polySia-NCAM expression with a polySia-binding fluorescent fusion protein, and polySia-NCAM expression was compared with clinical stage, age, MYCN amplification status, histology (INPC), and proliferation index (PI).\nPolySia-NCAM-positive neuroblastoma patients had more often metastases at diagnosis, and polySia-NCAM expression associated with advanced disease (P = 0.047). Most interestingly, absence of polySia-NCAM-expressing tumor cells in TMA samples, however, was a strong unfavorable prognostic factor for overall survival in advanced disease (P = 0.0004), especially when MYCN was not amplified. PolySia-NCAM-expressing bone marrow metastases were easily detected in smears, aspirates and biopsies.\nPolySia-NCAM appears to be a new clinically significant molecular marker in neuroblastoma, hopefully with additional value in neuroblastoma risk stratification.\nBACKGROUND\nMETHODS\nRESULTS\nCONCLUSION


Sisäiset tekijät/toimittajat

Last updated on 2019-21-08 at 21:10